Abstract
Background The elderly are highly vulnerable to severe Covid-19. Waning immunity and emergence of Omicron have caused concerns about reduced effectiveness of Covid-19 vaccines. The objective was to estimate vaccine effectiveness (VE) against severe Covid-19 among the elderly.
Methods This nationwide, register-based cohort analysis included all residents aged 70 years and over in Finland. The follow-up started on December 27, 2020, and ended on March 31, 2022. The outcomes of interest were Covid-19-related hospitalization and intensive care unit (ICU) admission timely associated with SARS-CoV-2 infection. VE was estimated as one minus the hazard ratio comparing the vaccinated and unvaccinated and taking into account time since vaccination. Omicron-specific VE was evaluated as the effectiveness observed since January 1, 2022.
Results The cohort included 896220 individuals. Comirnaty (BioNTech/Pfizer) VE against Covid-19-related hospitalization was 93% (95% CI 89%–95%) and 85% (95% CI 82%–87%) 14–90 and 91–180 days after the second dose; VE increased to 95% (95% CI 94%–96%) 14–60 days after the third dose. VE of other homologous and heterologous three dose series was similar. Protection against severe Covid-19 requiring ICU treatment was even better. Since January 1, 2022, Comirnaty VE was 98% (95% CI 92%–99%) and 92% (95% CI 87%–95%) 14–90 and 91–180 days after the second and 98% (95% CI 95%–99%) 14–60 days after the third dose.
Conclusions VE against severe Covid-19 is high among the elderly. It waned slightly after two doses, but a third restored the protection. VE against severe Covid-19 remained high even after the emergence of Omicron.
Competing Interest Statement
No financial conflicts related to the current work. Finnish Institute for Health and Welfare (THL) conducts Public-Private Partnership with vaccine manufacturers and has received research funding from Sanofi Inc., Pfizer Inc., and GlaxoSmithKline Biologicals SA for non-COVID-19-related studies. AAP has been an investigator in these studies but has received no personal remuneration.
Funding Statement
No external funding. This study was funded by the Finnish Institute for Health and Welfare (THL).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
A waiver of ethical approval was received from Professor Mika Salminen, Director of the Department for Health Security Finnish Institute for Health and Welfare (see supplement material).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
In the new version, the results have been updated by adding data from the second half of 2022 Q1 and by using a refined register-based definition of the relevant comorbidities that predispose to severe Covid-19, which is now given directly in the supplementary materials. This update had no major effect on the results other than an improved precision of the estimates for 2022 Q1.
Data Availability
By Finnish law, the authors are not permitted to share individual-level register data. The computing code is available upon request.
Abbreviations
- VE
- Vaccine effectiveness
- ICU
- Intensive care unit
- CI
- Confidence interval
- Q4
- Fourth calendar quarter
- Q1
- First calendar quarter
